Physician profile
David L Ross
NPI 1073516001
$16,723.55
in general payments reported to CMS, 2019-2025
60 companies · $2,378 in 2025
The $2,378 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,875 · 2020: $1,834 · 2021: $2,357 · 2022: $2,551 · 2023: $2,829 · 2024: $2,899 · 2025: $2,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,089 · Education: $17.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,089.36 |
| Education | $17.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,973.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,557.33 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,394.15 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,274.65 | 2019-2025 | |
| Amgen INC. | $1,160.20 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,031.25 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Abbvie INC. | $806.23 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novartis Pharmaceuticals Corporation | $792.01 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $722.65 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $704.03 | 2019-2025 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $571.79 | 2022-2025 | |
| Glaxosmithkline, LLC. | $563.87 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $535.41 | 2019-2024 | Xarelto |
| Lundbeck LLC | $425.88 | 2022-2025 | Vyepti, Rexulti, Brintellix |
| Merck Sharp & Dohme LLC | $405.82 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.